On December 11, Junhe Biotech announced that its self-developed injectable recombinant botulinum toxin type A has initiated a phase III clinical trial for the treatment of upper extremity cramps in adults and completed the enrollment of the first patient. The clinical trial was jointly led by Professor Li Fang of Huashan Hospital affiliated to Fudan University and Professor Jin Lingjing of Shanghai Sunshine Rehabilitation Center.

Zhitongcaijing · 3d ago
On December 11, Junhe Biotech announced that its self-developed injectable recombinant botulinum toxin type A has initiated a phase III clinical trial for the treatment of upper extremity cramps in adults and completed the enrollment of the first patient. The clinical trial was jointly led by Professor Li Fang of Huashan Hospital affiliated to Fudan University and Professor Jin Lingjing of Shanghai Sunshine Rehabilitation Center.